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Aims
A combined tracer evaluation of Ga-68 DOTATATE
(GaTate) and F-18 FDG (FDG) positron emission tomo-
graphy (PET-CT) and the ki-67 marker have potential
advantages over a single marker in determining the dif-
ferentiation of NETs. This study is sought to evaluate
their association and the potential role as predictive
markers for the management impact.
Methods
Twenty-one combined FDG-GaTate studies were per-
formed in various NETs lineages. A retrospective blinded
review was performed based on the grade of tumour dif-
ferentiation of ki-67 (European NET Society-ENETS) and
the correlated Krenning scales (Grade 1-4) of the FDG-
GaTATE PET-CT images. Subsequent management
impact (high and low) was determined by follow-up to
assess metabolic response of the pre and post treatment
GATATE-FDG PET-CT results.
Results
Significant correlation were noted in the Ki-67 (mean: 6.16
± 8.21 %) and the FDG SUVmax (mean: 5.72±5.24;g/dl p <
0.01) and inversely correlated with the Ga SUVmax (mean:
15.80 ±10.57g/dl; p< 0.05). Management impact in 12/21
patients was high (partial metabolic response or no recur-
rence) in 75% and low in 25% (progressive metabolic dis-
ease). The combined ki-67-GaTATE marker had
independent predictive significance for management
impact (likelihood ratio test for the whole model,
p=0.008).
Conclusion
Dual-tracer assessment of FDG-GaTate PET-CT provide a
valuable information on the NETs’ cellular differentiation.
Combination of ki-67-GaTATE may potentially be used as
a reliable predictive marker for the NETs’ management
impact.
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